![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/indivior-announces-dosing-of-first-subject-with-indv-2000-in-a-phase-2-study-assessing-the-safety-and-efficacy-of-indv-2000-in-individuals-with-opioid-use-disorder-302168484.html
https://www.prnewswire.com/news-releases/indivior-to-host-analyst-teach-in-event-in-new-york-city-reconfirms-full-year-2024-guidance-302153680.html
https://www.prnewswire.com/news-releases/indivior-announces-q1-2024-financial-results-302126698.html
https://www.prnewswire.com/news-releases/indivior-announces-publication-demonstrating-that-opvee-nalmefene-nasal-spray-rapidly-reverses-effects-of-opioid-induced-respiratory-depression-in-head-to-head-study-against-intranasal-naloxone-302085667.html
https://www.prnewswire.com/news-releases/court-provides-final-approval-of-settlement-with-direct-purchaser-class-in-the-multidistrict-antitrust-litigation-final-court-approval-concludes-the-antitrust-multidistrict-litigation-302075022.html
https://www.prnewswire.com/news-releases/indivior-announces-q3-2023-financial-results-301982004.html
https://www.fiercepharma.com/pharma/indivior-closes-out-yearslong-suboxone-antitrust-case-385m-settlement
https://www.prnewswire.com/news-releases/indivior-enters-an-exclusive-licensing-agreement-with-alar-pharmaceuticals-301954153.html
https://www.prnewswire.com/news-releases/indivior-publishes-real-world-data-showing-sublocade-may-reduce-non-fatal-overdoses-among-individuals-with-opioid-use-disorder-in-canada-301939365.html
https://www.fiercebiotech.com/medtech/click-therapeutics-teams-indivior-make-digital-therapeutics-substance-use-disorders